prof. dr. W. (Wijnand) Helfrich

Faculty of Medical Sciences

Telephone:

+31 50 361 3733

E-mail:

w.helfrich umcg.nl

Homepage ORCID Research Portal

Publications

Extracellular Vesicles in Cancer Immunotherapy

Ke, X., Helfrich, W. & Zhang, H., 1-Jan-2024, Extracellular Vesicles: From Bench to Bedside. Wang, Q. & Zheng, L. (eds.). Springer Nature, p. 467-474 8 p.

Research output: Chapter in Book/Report/Conference proceeding › Chapter › Academic › peer-review

Visible Light Control over the Cytolytic Activity of a Toxic Pore-Forming Protein

Volarić, J., van der Heide, N. J., Mutter, N. L., Samplonius, D. F., Helfrich, W., Maglia, G., Szymanski, W. & Feringa, B. L., 16-Feb-2024, In: ACS chemical biology. 19, 2, p. 451–461 11 p., 3c00640.

Research output: Contribution to journal › Article › Academic › peer-review

A Novel Bispecific Antibody for EpCAM-Directed Inhibition of the CD73/Adenosine Immune Checkpoint in Ovarian Cancer

Ploeg, E. M., Britsch, I., van Wijngaarden, A. P., Ke, X., Hendriks, M. A. J. M., Samplonius, D. F. & Helfrich, W., Jul-2023, In: Cancers. 15, 14, 15 p., 3651.

Research output: Contribution to journal › Article › Academic › peer-review

A Novel Bispecific Antibody for EpCAM-Directed Inhibition of the CD73/Adenosine Immune Checkpoint in Ovarian Cancer

Ploeg, E. M., Britsch, I., van Wijngaarden, A. P., Ke, X., Hendriks, M. A. J. M., Samplonius, D. F. & Helfrich, W., 17-Jul-2023, In: Cancers. 15, 14

Research output: Contribution to journal › Article › Academic › peer-review

Applications of Anti-Cytomegalovirus T Cells for Cancer (Immuno)Therapy

Britsch, I., van Wijngaarden, A. P. & Helfrich, W., Aug-2023, In: Cancers. 15, 15, 22 p., 3767.

Research output: Contribution to journal › Review article › peer-review

Applications of Anti-Cytomegalovirus T Cells for Cancer (Immuno)Therapy

Britsch, I., van Wijngaarden, A. P. & Helfrich, W., 25-Jul-2023, In: Cancers. 15, 15

Research output: Contribution to journal › Review article › peer-review

Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR

Ploeg, E. M., Samplonius, D. F., Xiong, X., Ke, X., Hendriks, M. A. J. M., Britsch, I., Van Wijngaarden, A. P., Zhang, H. & Helfrich, W., 21-Sept-2023, In: Journal for immunotherapy of cancer. 11, 9, 15 p., e006837.

Research output: Contribution to journal › Article › Academic › peer-review

Novel Fab-peptide-HLA-I fusion proteins for redirecting pre-existing anti-CMV T cell immunity to selective eliminate carcinoma cells

Britsch, I., van Wijngaarden, A. P., Ke, X., Hendriks, M. A. J. M., Samplonius, D. F., Ploeg, E. M. & Helfrich, W., 2023, In: OncoImmunology. 12, 1, 2207868.

Research output: Contribution to journal › Article › Academic › peer-review

A proof-of-concept study on the use of a fluorescein-based 18F-tracer for pretargeted PET

Helbert, H., Ploeg, E. M., Samplonius, D. F., Blok, S. N., Antunes, I. F., Böhmer, V. I., Luurtsema, G., Dierckx, R. A. J. O., Feringa, B. L., Elsinga, P. H., Szymanski, W. & Helfrich, W., 3-Mar-2022, In: EJNMMI Radiopharmacy and Chemistry. 7, 1, 11 p., 3.

Research output: Contribution to journal › Article › Academic › peer-review

Impact of cumulative complications on 1-year treatment-related healthcare costs in patients with colorectal peritoneal metastases undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy

van der Zant, F. A., Kooijman, B. J. L., Hentzen, J. E. K. R., Helfrich, W., Ploeg, E. M., van Ginkel, R. J., van Leeuwen, B. L., Been, L. B., Klaase, J. M., Hemmer, P. H. J., van der Hilst, C. S. & Kruijff, S., 2-Sept-2022, In: BJS open. 6, 5, 9 p., zrac109.

Research output: Contribution to journal › Article › Academic › peer-review